免疫检查点抑制剂治疗肺癌患者的静脉血栓栓塞发生率与风险评估
该回顾性队列研究纳入345例非小细胞肺癌患者,比较单药免疫检查点抑制剂(ICI)与铂类化疗患者6个月静脉血栓栓塞(VTE)累积发生率及Khorana评分(KS)表现。化疗组6个月VTE累积发生率为7.1%,ICI组为4.5%(HR=1.6,95%CI 0.66-3.9)。KS未能识别ICI治疗的高危患者,提示需开发ICI特异性风险模型。
要点
- 铂类化疗患者6个月VTE累积发生率7.1%,高于ICI单药患者的4.5%。
- 化疗组高危KS患者VTE风险有升高趋势(HR 3.04,95%CI 0.82-11.22)。
- ICI组高危KS患者VTE风险反而有降低趋势(HR 0.17,95%CI 0.02-1.36)。
核心结论
- 铂类化疗的NSCLC患者VTE发生率高于ICI单药患者,但相对估计精确度低。
- KS未能识别ICI治疗的高危患者,需要ICI特异性风险模型。
研究设计与样本
- 回顾性队列研究,纳入345例开始ICI或铂类化疗的NSCLC患者。
- ICI组176例接受单药ICI,化疗组169例接受铂类化疗。
- 采用竞争风险模型计算6个月VTE累积发生率和风险比(HR)。
主要发现
- 化疗组6个月VTE累积发生率为7.1%,ICI组为4.5%(HR=1.6,95%CI 0.66-3.9)。
- 化疗组高危KS相比低危KS的VTE HR为3.04(95%CI 0.82-11.22)。
- ICI组高危KS相比低危KS的VTE HR为0.17(95%CI 0.02-1.36)。
临床怎么用
- 对接受铂类化疗的NSCLC患者应关注VTE风险,可考虑KS评估。
- 对接受ICI单药治疗的患者,KS不适用于VTE风险分层。
局限性
- 回顾性研究设计。
- 相对风险估计精确度低,置信区间宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are scarce data on venous thromboembolism (VTE) rates among non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICI). The Khorana Score (KS), used to guide thromboprophylaxis in cancer patients, was validated in patients receiving chemotherapy. OBJECTIVE: To assess VTE rates and KS performance among NSCLC patients treated with ICI or chemotherapy. METHODS: We performed a retrospective cohort study of NSCLC patients starting either ICI or platinum-based chemotherapy. The 6-month cumulative incidence of VTE in the ICI and chemotherapy cohorts and hazard ratios (HR) with 95% confidence intervals (CI) were calculated, using death as a competing risk. Subgroup analysis of low (0-1) and high (≥2) KS risk groups was performed. RESULTS: The study included 345 NSCLC patients receiving single agent ICI (n = 176) or chemotherapy (n = 169). The 6-month cumulative incidence of VTE was 7.1% in the chemotherapy cohort and 4.5% in the ICI cohort (HR for chemotherapy = 1.6, 95% CI 0.66-3.9). Among chemotherapy treated patients, the high-risk KS group had a trend toward a higher VTE incidence, compared with patients with a low-risk KS (HR 3.04, 95% CI 0.82-11.22). Among ICI-treated patients, the high-risk KS group had a trend toward a lower VTE incidence compared with the low-risk group (HR 0.17, 95% CI 0.02-1.36). CONCLUSIONS: VTE rates were higher among NSCLC patients treated with platinum-based chemotherapy than those treated with ICI alone, though the precision of the relative estimate is low. The KS did not identify high-risk ICI-treated patients, suggesting that an ICI-specific risk model is warranted.
引用
- Icht O, Darzi N, Shimony S, et al. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemost. 2021. PMID: 33605020. doi:10.1111/jth.15272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。